Daniel Bock

Daniel Bock has extensive experience in the biotech and pharmaceutical industry. Daniel currently serves as the Chief Scientific Officer at sterna biologicals GmbH. Prior to this role, Daniel worked as an Independent Expert & Consultant, providing support to various biopharmaceutical companies and start-up projects. Daniel'sareas of expertise include diagnostics, medical devices, and pharmaceutical R&D. Daniel has been involved in a wide range of projects such as non-invasive therapy, preclinical research, drug discovery, biomarker technology, and nanocarrier drug delivery. Daniel has also successfully sold a RNA-based immuno-oncology treatment to a major pharmaceutical company. Before their consultancy work, they held leadership positions at Revotar Biopharmaceuticals AG, where they contributed to the discovery and development of novel anti-inflammatory drugs. Daniel has also worked as a Postdoctoral Scientist at Novartis Research Institute. Daniel's work experience demonstrates their strong background and knowledge in R&D, clinical development, and biological sciences.

Daniel Bock holds a PhD degree from Medical School Hannover / University Hannover. However, no specific information regarding the duration or field of study is provided.